These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 9526816)
1. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Ellen RL; McPherson R Am J Cardiol; 1998 Feb; 81(4A):60B-65B. PubMed ID: 9526816 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Wang TD; Chen WJ; Lin JW; Cheng CC; Chen MF; Lee YT Atherosclerosis; 2003 Oct; 170(2):315-23. PubMed ID: 14612213 [TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy. Farnier M; Ducobu J; Bryniarski L Curr Med Res Opin; 2011 Nov; 27(11):2165-73. PubMed ID: 21973199 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Didangelos TP; Carina MV; Kranitsas DF; Kontopoulos AG Am J Cardiol; 1997 Sep; 80(5):608-13. PubMed ID: 9294990 [TBL] [Abstract][Full Text] [Related]
5. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335 [TBL] [Abstract][Full Text] [Related]
6. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia. Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157 [TBL] [Abstract][Full Text] [Related]
7. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. Derosa G; D'Angelo A; Franzetti IG; Ragonesi PD; Gadaleta G; Scalise F; Ciccarelli L; Piccinni MN; Cicero AF J Clin Pharm Ther; 2009 Jun; 34(3):267-76. PubMed ID: 19650249 [TBL] [Abstract][Full Text] [Related]
10. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Adkins JC; Faulds D Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964 [TBL] [Abstract][Full Text] [Related]
11. Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia. Farnier M Expert Rev Cardiovasc Ther; 2012 May; 10(5):565-75. PubMed ID: 22651832 [TBL] [Abstract][Full Text] [Related]
12. [Long-term treatment of combined hyperlipidemia with a combination of fluvastatin and fenofibrate]. Widimský J; Hulínský V; Balazovjech I; Lánská V Vnitr Lek; 1999 Apr; 45(4):210-6. PubMed ID: 11045181 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Bruckert E; De Gennes JL; Malbecq W; Baigts F Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. Farnier M; Ducobu J; Bryniarski L Am J Cardiol; 2010 Sep; 106(6):787-92. PubMed ID: 20816118 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Grundy SM; Vega GL; Yuan Z; Battisti WP; Brady WE; Palmisano J Am J Cardiol; 2005 Feb; 95(4):462-8. PubMed ID: 15695129 [TBL] [Abstract][Full Text] [Related]
16. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia. Schonfeld G; Aguilar-Salina C; Elias N Am J Cardiol; 1998 Feb; 81(4A):43B-46B. PubMed ID: 9526813 [TBL] [Abstract][Full Text] [Related]
17. Comparison of statins in hypertriglyceridemia. Stein EA; Lane M; Laskarzewski P Am J Cardiol; 1998 Feb; 81(4A):66B-69B. PubMed ID: 9526817 [TBL] [Abstract][Full Text] [Related]
18. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study. Farnier M; Steinmetz A; Retterstøl K; Császár A Clin Ther; 2011 Jan; 33(1):1-12. PubMed ID: 21397769 [TBL] [Abstract][Full Text] [Related]
19. [The fixed combination of pravastatin and fenofibrate: what can it provide?]. Díaz Rodríguez Á Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541 [TBL] [Abstract][Full Text] [Related]
20. Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy. Ouwens MJ; Nauta J; Ansquer JC; Driessen S Curr Med Res Opin; 2015 Dec; 31(12):2273-85. PubMed ID: 26397380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]